Truist Securities Maintains Buy on Adverum Biotechnologies, Lowers Price Target to $40
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained its Buy rating on Adverum Biotechnologies (NASDAQ:ADVM) but has lowered the price target from $60 to $40.
August 14, 2024 | 1:57 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Truist Securities has maintained its Buy rating on Adverum Biotechnologies but has lowered the price target from $60 to $40.
The maintenance of the Buy rating is positive, but the lowered price target indicates a more cautious outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100